Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients

Basit Öğe Kaydı
dc.authoridYildirim, Derya/0000-0003-2771-7725|Erdemli, Haci Kemal/0000-0002-3399-4676|Duranay, Murat/0000-0002-2893-4484
dc.contributor.authorBavbek, Nuket
dc.contributor.authorCeri, Mevlut
dc.contributor.authorAkdeniz, Derya
dc.contributor.authorKargili, Ayse
dc.contributor.authorDuranay, Murat
dc.contributor.authorErdemli, Kemal
dc.contributor.authorAkcay, Ali
dc.date.accessioned2025-10-24T18:09:44Z
dc.date.available2025-10-24T18:09:44Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Coagulation abnormalities have been reported in familial Mediterranean fever (FMF) patients with amyloidosis and nephrotic syndrome; but there is not enough data about the continuity of the thrombogenic activity in FMF patients in clinical remission. The purpose of this study was to assess thrombin activatable fibrinolysis inhibitor (TAFI) levels and its relationship with fibrinolytic activity and also evaluate relationships between mutations and clinical signs in attack-free patients without amyloidosis. Methods: Seventy-nine FMF patients and 40 healthy adults were included. The study group was divided into five groups as follows: first group, homozygote M694V; second group, homozygote M680I; third group, M694V in one allele, the other allele have other mutations or not; fourth group, other mutations; and fifth group, no mutation. Results: Serum TAFI levels were significantly increased in patients compared with healthy individuals (116.64 +/- 21.8 vs. 78.48 +/- 19.7 mu g/mL, p<0.001) and a positive correlation was detected between TAFI antigen level and erythrocyte sedimentation rate and C-reactive protein levels (r = 0.247, p = 0.029 and r = 0.252, p = 0.032, respectively). Mean fibrinogen and TAFI levels were significantly higher in Group 1 than the other groups (p = 0.04 and p = 0.001, respectively) and in Group 3 it was higher than Groups 2, 4 and 5 (p = 0.04 and p = 0.001, respectively). Conclusions: High level of TAFI antigen in attack-free period of FMF disease shows ongoing subclinical inflammation and hypercoagulability. Clinicians should be careful about thrombosis even in patients at clinical remission. Also, genetic tests must be considered to predict clinical outcome and to reduce complications of FMF disease.
dc.identifier.doi10.3109/0886022X.2014.886935
dc.identifier.endpage747
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue5
dc.identifier.pmid24580410
dc.identifier.scopus2-s2.0-84901915208
dc.identifier.scopusqualityQ2
dc.identifier.startpage743
dc.identifier.urihttps://doi.org/10.3109/0886022X.2014.886935
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3786
dc.identifier.volume36
dc.identifier.wosWOS:000336743500014
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherInforma Healthcare
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectFamilial Mediterranean fever; hypercoagulability; M694V mutation; TAFI
dc.titleHigher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu